Daiichi Sankyo Korea

Daiichi Sankyo Korea is the South Korean subsidiary of the global pharmaceutical company Daiichi Sankyo, headquartered in Japan. The company is a dominant player in the Korean cardiovascular market, led by its flagship anticoagulant Lixiana and a robust portfolio of hypertension treatments like Olmetec and Sevikar. In recent years, the subsidiary has pivoted its strategic focus toward oncology, spearheading the local clinical development and commercialization of advanced antibody-drug conjugates (ADCs). Its most notable oncology asset, Enhertu, has significantly impacted the treatment landscape for HER2-positive cancers in Korea. The company operates as a comprehensive pharmaceutical entity, managing regulatory affairs, medical relations, and large-scale commercial operations within the region.